Covaxin demonstrates protection against deadly new variants

A study published by Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively.

A modest reduction in neutralization by a factor of 1.95 was observed against B1617 variant compared to vaccine variant.